Delivery Order SPE2DB20D1100-SPE2DB25FD7T5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,985.82 to AmerisourceBergen Drug Corp for ZOLADEX 3.6 mg implant syringes, with an ultimate completion date of August 13, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed price pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply framework. The pharmaceutical will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,754.58 firm fixed price delivery order to AmerisourceBergen Drug Corp's Corporate Office division. The contract is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, with a completion date of October 16, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded multiple federal contracts to provide a wide range of prescription medications, medical supplies, and equipment to various government agencies and healthcare programs....
- This is a Delivery Order (DO) awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $20,303.52, is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, a specialty pharmaceutical product. The contract has a firm fixed-price pricing type and an ultimate completion date of April 10, 2023. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,297.50 firm fixed-price contract is for the supply of ZOLADEX 10.8 MG IMPLANT SYRNS, a type of pharmaceutical product. The order has a completion date of July 25, 2025 and is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $22,314.00, is for the supply of the medication ZOLADEX 10.8 MG IMPLANT SYRNS. The contract is a firm fixed-price delivery order without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,985.82 firm fixed-price contract is for the supply of ZOLADEX 3.6 MG IMPLANT SYRNS, a specialty medication. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a subsidiary of the global pharmaceutical distribution company AmerisourceBergen Corporation. The $1,873.74 firm fixed price delivery order is for the supply of ZOLADEX 3.6 MG IMPLANT SYRNS, a specialty pharmaceutical product. This award is associated with a larger indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp, valued at up to $999,999,999.00 through December 31,...
- This federal contract award, valued at $1,873.74, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office Division. The contract is for the delivery of the pharmaceutical product ZOLADEX 3.6 MG IMPLANT SYRNS, with a completion date of May 10, 2024. Amerisourcebergen, a large pharmaceutical distribution company, holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to...
- This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract is a delivery order with a firm fixed price and a ceiling value of $1,859.50. The contract is not set aside and will deliver ZOLADEX 10.8 MG IMPLANT SYRNS to the government. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,297.50 on August 12, 2025, for the supply of Zoladex 10.8 mg implant syringes, with a completion date of September 3, 2025. This non-set-aside, competitively awarded contract carries firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office location...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD7T5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for ZOLADEX 3.6 mg implant syringes under a firm fixed price contract valued at $1,323.88. This non-set-aside award, issued on July 31, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion comprehensive pharmaceutical support vehicle running through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor serving military and veteran healthcare systems. The company maintains an extensive portfolio of federal contracts with the Defense Logistics Agency, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The SPE2DX IDC serves as a flexible global pharmaceutical support vehicle enabling AmerisourceBergen to supply a vast range of products to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems worldwide, positioning the company as a key provider within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.3k | 7/31/25 |